Latest News and Press Releases
Want to stay updated on the latest news?
-
Lexeo Therapeutics Announces Progress in FDA Discussions for Accelerated Approval and Positive Interim Clinical Data for LX2006 in FA Cardiomyopathy
-
Lexeo Therapeutics Reports Second Quarter 2025 Financial Results and Operational Highlights
-
Lexeo Therapeutics Announces FDA Breakthrough Therapy Designation for LX2006 in Friedreich Ataxia
-
Lexeo Therapeutics Announces $80 Million Equity Financing to Further Advance Development of Transformative Genetic Medicines for Cardiovascular Diseases
-
Lexeo Therapeutics Reports First Quarter 2025 Financial Results and Operational Highlights
-
Lexeo Therapeutics Announces Positive Interim Phase 1/2 Data for LX2006 in Friedreich Ataxia Cardiomyopathy Supporting Advancement to Registrational Study
-
Lexeo Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights